FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond ...

"Milford Regional Medical Center is a highly respected community hospital with a strong commitment to clinical excellence," said Peter Ferrari, President of Shields Health. We are proud to collaborate ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...

PET scans may serve as both a diagnostic and prognostic tool in giant cell arteritis (GCA), according to a new study. In over 100 patients with GCA who underwent 18 F-fluorodeoxyglucose (FDG) PET ...

Positron emission tomography (PET) is an imaging modality to better understand the pathophysiology of a disease at molecular level and typically referred to as molecular imaging. It reveals the ...

A macrophage-targeted PET/CT tracer predicts anti-TNF response in rheumatoid arthritis at baseline and four weeks, enabling ...

Professor of Medical Imaging at the University of Arizona Lars Furenlid, the project’s lead researcher. Professor of Radiology at UMass Chan Medical School Michael King. In order to better study and ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University Hospital Essen on the PROMISE-PET registry 1, defining the potential prognostic ...

Researchers from Japan have uncovered direct evidence showing how ketamine exerts its rapid antidepressant effects in ...